IP Library Assignment 025445/0807
Patent Assignment
Reel/Frame 025445/0807

Change of Name

Recorded: 2010-12-07 Pages: 6
Assignor
FACET BIOTECH CORPORATION
Executed: 2010-09-08
Assignee
ABBOTT BIOTHERAPEUTICS CORP.
1500 SEAPORT BLVD., REDWOOD CITY, CALIFORNIA, 94063
Covered Properties (64)
Bispecific Antibody Heterodimers
Patent: 5,932,448 →
Application: 07/801,798 →
Cross-Reacting Monoclonal Antibodies Specific for E- and P-Selectin
Patent: 5,622,701 →
Application: 08/259,963 →
Bispecific Antibody Effective to Treat B-Cell Lymphoma and Cell Line
Patent: 6,129,914 →
Application: 08/397,411 →
Humanized Antibodies Reactive with L-Selectin
Patent: 6,210,671 →
Application: 08/579,378 →
Cross-Reacting Monoclonal Antibodies Specific for E-Selectin and P-Selectin
Patent: 6,210,670 →
Application: 08/619,491 →
Monoclonal Antibodies Specific for the Platelet Derived Growth Factor Beta Receptor and Methods of Use Thereof
Patent: 5,882,644 →
Application: 08/621,751 →
Fas Ligand Fusion Proteins and Their Uses
Patent: 6,046,310 →
Application: 08/815,190 →
Method of Preventing Acute Rejection Following Solid Organ Transplantation
Patent: 6,013,256 →
Application: 08/934,841 →
Humanized Antibodies to Gamma-Interferon
Patent: 6,329,511 →
Application: 09/450,520 →
Animal Model for Psoriasis for the Prevention and Treatment of Psoriasis in Humans
Patent: 6,410,824 →
Application: 09/457,912 →
Novel Methods of Diagnosing Cancer, Compositions, and Methods of Screening for Cancer Modulators
Patent: 6,566,502 →
Application: 09/608,821 →
Humanized Antibodies Against CD3
Patent: 7,381,803 →
Application: 09/618,380 →
Novel Methods for Detection and Diagnosing of Breast Cancer
Patent: 6,750,013 →
Application: 09/747,371 →
Publication: US 2002/0006616
Humanized Antibodies to Gamma-Interferon
Patent: 7,183,390 →
Application: 09/992,524 →
Publication: US 2002/0091240
Method of treating psoriasis using anti-interleukin 12 antibody
Application: 10/108,191 →
Publication: US 2002/0194631
Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer
Patent: 7,189,507 →
Application: 10/173,999 →
Publication: US 2004/0005563
Anti-Hla-Dr Antibodies and the Methods of Using Thereof
Patent: 6,894,149 →
Application: 10/268,883 →
Publication: US 2003/0138862
Stable liquid pharmaceutical formulation of IgG antibodies
Application: 10/291,528 →
Publication: US 2003/0138417
Anti-CCR5 Antibody
Patent: 7,122,185 →
Application: 10/371,483 →
Publication: US 2003/0228306
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 7,288,248 →
Application: 10/383,447 →
Publication: US 2004/0096392
Treatment of Inflammatory Bowel Diseases with Anti-Ip-10 Antibodies
Patent: 7,935,793 →
Application: 10/581,468 →
Publication: US 2008/0063646
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,217,797 →
Application: 10/687,118 →
Publication: US 2005/0032114
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,276,589 →
Application: 10/724,274 →
Publication: US 2005/0054834
Antibodies Against GPR64 and Uses Thereof
Patent: 7,276,372 →
Application: 10/741,657 →
Publication: US 2004/0197325
Amphiregulin Antibodies and Their Use to Treat Cancer and Psoriasis
Patent: 7,223,393 →
Application: 10/774,076 →
Publication: US 2004/0210040
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,361,740 →
Application: 10/822,300 →
Publication: US 2005/0014934
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,285,268 →
Application: 10/830,956 →
Publication: US 2005/0163769
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Patent: 7,217,798 →
Application: 10/966,673 →
Publication: US 2005/0226864
Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
Patent: 7,399,469 →
Application: 11/089,872 →
Publication: US 2005/0260212
Use of Anti-ALPHA5BETA1 Antibodies to Inhibit Cancer Cell Proliferation
Patent: 7,662,384 →
Application: 11/090,331 →
Publication: US 2005/0260210
Alteration of Fcrn Binding Affinities or Serum Half-Lives of Antibodies by Mutagenesis
Patent: 7,365,168 →
Application: 11/102,621 →
Publication: US 2005/0276799
Stable Lyophilized Pharmaceutical Formulation of Igg Antibodies
Patent: 7,592,004 →
Application: 11/250,835 →
Publication: US 2006/0029599
Anti-CCR5 Antibody
Patent: 7,851,600 →
Application: 11/581,944 →
Publication: US 2008/0107595
Anti-CCR5 Antibody
Patent: 7,666,419 →
Application: 11/581,945 →
Publication: US 2007/0031408
Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer
Patent: 7,435,589 →
Application: 11/625,458 →
Publication: US 2007/0154928
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Patent: 7,732,570 →
Application: 11/803,694 →
Publication: US 2008/0287657
Compositions and Methods Using Anti-CS1 Antibodies to Treat Multiple Myeloma
Patent: 7,842,293 →
Application: 11/835,245 →
Publication: US 2008/0124332
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 7,785,816 →
Application: 11/837,333 →
Publication: US 2008/0044840
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 7,824,678 →
Application: 11/837,337 →
Publication: US 2008/0160012
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,879,987 →
Application: 11/840,854 →
Publication: US 2009/0259031
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,776,585 →
Application: 11/840,863 →
Publication: US 2008/0026458
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 8,017,116 →
Application: 11/840,871 →
Publication: US 2008/0026033
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Patent: 7,897,148 →
Application: 11/852,147 →
Publication: US 2008/0260732
Antibodies Against GPR64 and Uses Thereof
Patent: 7,547,544 →
Application: 11/852,155 →
Publication: US 2008/0107642
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 7,674,883 →
Application: 11/855,073 →
Publication: US 2008/0175846
Tethered Vectors for Cell Surface Immunoglobulin Display
Patent: 7,732,195 →
Application: 11/933,819 →
Publication: US 2009/0111126
Therapeutic Use of Anti-Tweak Receptor Antibodies
Patent: 9,056,908 →
Application: 12/185,689 →
Publication: US 2009/0074762
Antibodies Against GPR64 and Uses Thereof
Patent: 7,807,163 →
Application: 12/203,868 →
Publication: US 2009/0117036
Immunoglobulin Display Vectors
Patent: 7,947,495 →
Application: 12/263,272 →
Publication: US 2009/0136950
Methods of Screening Complex Protein Libraries to Identify Altered Properties
Patent: 8,633,139 →
Application: 12/340,279 →
Publication: US 2013/0338017
Stable Lyophilized Pharmaceutical Formulation of Igg Antibodies
Patent: 8,298,530 →
Application: 12/540,320 →
Publication: US 2010/0055097
Method for Treating Multiple Sclerosis Patients with Anti-IL2R Antibodies
Application: 12/549,501 →
Publication: US 2010/0055098
Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
Application: 12/642,687 →
Publication: US 2010/0291111
Mammalian Cell-Based Immunoglobulin Display Libraries
Patent: 8,163,546 →
Application: 12/748,247 →
Publication: US 2011/0008883
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Patent: 8,624,007 →
Application: 12/751,914 →
Publication: US 2011/0183412
Anti-Tnf-Alpha Antibodies and Their Uses
Patent: 8,722,860 →
Application: 12/761,745 →
Publication: US 2010/0266613
Methods for Monitoring the Efficacy of Anti-Il-2R Antibodies in Multiple Sclerosis Patients
Application: 12/768,131 →
Publication: US 2010/0273204
Anti-Vegf Antibodies and Their Uses
Patent: 9,079,953 →
Application: 12/817,800 →
Publication: US 2010/0322931
Use of an Immunoregulatory Nk Cell Population for Monitoring the Efficacy of Anti-Il-2R Antibodies in Multiple Sclerosis Patients
Application: 12/872,886 →
Publication: US 2011/0053209
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Patent: 8,257,708 →
Application: 12/892,725 →
Publication: US 2011/0038864
Compositions and Methods Using Anti-CS1 Antibodies to Treat Multiple Myeloma
Application: 12/903,051 →
Publication: US 2011/0165154
Anti-Egfr Antibodies and Their Uses
Patent: 8,658,175 →
Application: 12/914,729 →
Publication: US 2011/0117110
Use of Immunoregulatory Nk Cell Populations for Predicting the Efficacy of Anti-Il-2R Antibodies in Multiple Sclerosis Patients
Application: 12/915,659 →
Publication: US 2011/0104153
CTLA4 Proteins and Their Uses
Application: 61/313,516 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 28, 1996
From: CHANG, CHUNG NAN; LANDOLFI, NICHOLAS; MARTIN, ULRICH
To: PROTEIN DESIGN LABS, INC.; BOEHRINGER MANNHEIM GMBH
Reel/Frame 008148/0308 →
Assignment of Assignor's Interest Aug 13, 2003
From: BHASKAR, VINAY; CALLE, AGUSTIN DE LA; LAW, DEBBIE; CARAS, INGRID
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014391/0598 →
Assignment of Assignor's Interest Aug 18, 2003
From: OLSON, WILLIAM C.; MADDON, PAUL J.
To: PROGENICS PHARMACEUTICALS, INC.
Reel/Frame 014393/0471 →
Assignment of Assignor's Interest Aug 18, 2003
From: TSURUSHITA, NAOYA; HINTON, PAUL R.; VASQUEZ, MAXIMILLANO
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014392/0780 →
Assignment of Assignor's Interest Sep 25, 2003
From: VASQUEZ, MAXIMILIANO; LANDOLFI, NICHOLAS F.; TSURUSHITA, NAOYA; QUEEN, CARY L.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014562/0232 →
Assignment of Assignor's Interest Feb 6, 2004
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014967/0744 →
Assignment of Assignor's Interest Oct 14, 2004
From: HINTON, PAUL R; TSURUSHITA, NAOYA; TSO, J. YUN; VASQUEZ, MAXIMILIANO
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 015250/0453 →
Assignment of Assignor's Interest Jan 17, 2006
From: ROCHE DIAGNOSTICS GMBH
To: PDL BIOPHARMA, INC.
Reel/Frame 017015/0693 →
Change of Name Feb 17, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017186/0110 →
Assignment of Assignor's Interest Apr 5, 2006
From: KAISHEVA, ELIZABET A.; GUPTA, SUPRIYA; DUVUR, SHANTI G.; SUBRAMANIAN, MALATHY
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017427/0209 →
Change of Name Apr 7, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017439/0502 →
Merger Apr 11, 2006
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017455/0630 →
Change of Name Apr 13, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017465/0495 →
Change of Name May 1, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017555/0284 →
Merger May 1, 2006
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017555/0288 →
Change of Name May 19, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017636/0787 →
Change of Name May 22, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017655/0436 →
Assignment of Assignor's Interest May 22, 2006
From: MCPHATE GREEN, JENNIFER; TSO, J. YUN
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017649/0446 →
Assignment of Assignor's Interest Jul 21, 2006
From: BALASA, BALAJI; TSURUSHITA, NAOYA; LANDOLFI, NICHOLAS F.
To: PDL BIOPHARMA, INC.
Reel/Frame 017974/0498 →
Assignment of Assignor's Interest Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0275 →
Assignment of Assignor's Interest Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0269 →
Assignment of Assignor's Interest Apr 13, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022537/0440 →
Assignment of Assignor's Interest Apr 13, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022537/0360 →
Assignment of Assignor's Interest Aug 5, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023056/0251 →
Assignment of Assignor's Interest Sep 18, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023245/0973 →